If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2020-12-02
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECOMMENDED BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR THE TREATMENT OF IGA NEPHROPATHY
2020-11-10
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON LICENSING PARTNER CALLIDITAS THERAPEUTICS REPORTING TOPLINE RESULTS FROM PIVOTAL PHASE 3 NEFIGARD TRIAL
2020-11-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2020
2020-11-03
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE OF FIRST PATIENT DOSED IN PHASE 2B REGISTRATION CLINICAL TRIAL OF TRODELVY TM (SACITUZUMAB GOVITECAN) FOR THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN CHINA
2020-11-02
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF TRODELVY TM FOR METASTATIC BREAST CANCER IN CHINA
2020-11-01
ANNOUCEMENT OF FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
2020-10-27
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON THE COMPLETION OF PHASE 3 BRIDGING CLINICAL TRIAL OF XERAVA TM (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA
